サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1797236

深部静脈血栓症（DVT）の世界市場

Deep Vein Thrombosis (DVT)

出版日
ページ情報
英文 378 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.53円
深部静脈血栓症（DVT）の世界市場
出版日: 2025年08月25日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 378 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

深部静脈血栓症（DVT）の世界市場は2030年までに10億米ドルに達する見込み

2024年に6億8,100万米ドルと推定される深部静脈血栓症（DVT）の世界市場は、分析期間2024-2030年にCAGR 7.3％で成長し、2030年には10億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである抗凝固剤は、CAGR 8.4%を記録し、分析期間終了時には7億2,020万米ドルに達すると予測されます。ヘパリンセグメントの成長率は、分析期間中CAGR 4.7%と推定されます。

米国市場は1億8,550万米ドルと推定、中国はCAGR11.6%で成長予測

米国の深部静脈血栓症（DVT）市場は、2024年に1億8,550万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに2億2,060万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは11.6%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.5%と7.1%と予測されています。欧州では、ドイツがCAGR 4.8%で成長すると予測されています。

世界の深部静脈血栓症（DVT）市場- 主要動向と促進要因まとめ

なぜ深部静脈血栓症は世界の健康問題の高まりと考えられているのか？

深部静脈血栓症（DVT）は、その有病率の上昇、重篤な合併症、しばしば静かに進行することから、世界中でますます重大な健康問題となっています。DVTは深部静脈（一般的には下肢）に血栓が形成されることで発症し、血栓が外れて肺に達すると肺塞栓症などの生命を脅かす疾患につながる可能性があります。DVTの管理における大きな課題のひとつは、自覚症状がないまま発症することが多いため、早期発見が難しく、自覚症状と予防ケアの必要性が強調されていることです。座りっぱなしの生活、長時間体を動かさない生活、肥満、喫煙、高齢化などがDVT患者を増加させています。長距離の移動、特に飛行機での移動、手術後や慢性疾患中の長期の安静は、血栓形成の誘因となることが知られています。さらに、遺伝性の血液凝固障害を持つ人、がん患者、妊娠中の女性はリスクが高くなります。病院では、特に人工股関節置換術や人工膝関節置換術などの整形外科手術後に、DVTはよく見られる術後合併症です。世界人口の高齢化と慢性疾患の流行に伴い、ヘルスケアシステムにおけるDVTの負担は増加すると予想されています。DVTが特に危険なのは、再発しやすいことと、運動能力や生活の質に影響を及ぼす血栓後症候群などの長期的な合併症を引き起こす可能性があることです。DVTの潜在的な重症度と頻度を考慮すると、DVTは公衆衛生の優先事項であり、スクリーニング、啓発キャンペーン、予防戦略の強化が求められています。

技術革新と臨床革新はDVTの診断と治療をどのように改善していますか？

診断技術と治療アプローチの進歩により、深部静脈血栓症の早期発見、管理、治療が大幅に向上しています。標準的な非侵襲的画像診断技術としてデュプレックス超音波検査が採用されたことで、DVT診断の精度とアクセスが大幅に改善され、臨床医は血流を可視化し、血栓をリアルタイムで検出できるようになりました。高感度Dダイマー血液検査もまた、低リスクから中等度のDVT患者を除外するのに不可欠なツールとして登場し、不必要な画像診断を減らすことができるようになりました。治療面では、抗凝固薬が第一選択薬であることに変わりはなく、定期的な血液モニタリングと食事制限が必要なワルファリンなどの従来の治療薬に比べ、新しい直接経口抗凝固薬（DOAC）は利便性と安全性に優れています。これらの新薬はDVTの長期管理を簡素化し、病院での再入院を減少させました。インターベンショナルラジオロジーの技術革新により、カテーテル直接血栓溶解療法や機械的血栓除去術が導入され、これらは血栓が大きい場合や生命を脅かす場合に特に有用です。また、圧迫療法やウェアラブル医療機器も、症状の管理や再発リスクの低減に使用されています。さらに、デジタルヘルスプラットフォームや遠隔医療は、特に遠隔地や十分なサービスを受けていない地域において、患者のアドヒアランスやフォローアップケアを向上させています。臨床ガイドラインは、リスク層別化と個別ケアプランを強調するように進化しており、高リスク集団においてより積極的なアプローチを奨励しています。血液凝固リスクの遺伝子マーカーやバイオマーカーの研究が進むにつれ、DVT管理の個別化・精密化が進み、DVTの臨床的・経済的負担が軽減されるでしょう。

どのような市場動向がDVT治療薬とモニタリングツールの需要拡大に影響を与えていますか？

深部静脈血栓症の治療、モニタリング技術、予防ソリューションに対する世界の需要の高まりには、いくつかの新たな市場動向が寄与しています。顕著な動向の一つは、心血管系疾患、がん、糖尿病などのDVTになりやすい慢性疾患や病態の発生率の上昇で、特に高齢化が進んでいます。ヘルスケアシステムが高齢者や複雑な合併症を持つ人々のニーズに適応するにつれ、DVTの予防と管理は日常的なケアに広く組み込まれるようになっています。特に整形外科手術や心臓血管外科手術の増加も、術後の患者が血栓形成のリスクを高めるため、市場の成長に影響を与えています。これと並行して、外来手術センターの拡大や入院期間の短縮が、在宅抗凝固療法やモバイルモニタリング機器に対する需要を生み出しています。ウェアラブル医療技術やデジタル治療薬が人気を集め、循環器系の健康状態や服薬アドヒアランスをリアルタイムで追跡できるようになっています。また、公衆衛生団体や患者擁護団体による啓発キャンペーンによって、患者教育や自己管理が重視されるようになっています。医薬品分野では、抗凝固薬メーカー間の競合が激化しており、副作用の少ない、より安全で効果的な製剤を開発するための研究開発への投資が促されています。ヘルスケアでは、予測分析とAIの利用が増加しており、リスクのある人物を早期に特定し、先手を打って介入できるようになっています。世界的には、予防医療を推進するヘルスケア政策と価値ベースの償還モデルが、包括的なDVT予防プロトコルの採用を医療提供者に促しています。このような市場力学により、イノベーション、アクセシビリティ、予防が一体となったエコシステムが構築され、深刻かつ深刻な健康問題に対処できるようになっています。

世界のDVT管理市場の拡大を促進する主な要因は何ですか？

深部静脈血栓症市場の成長は、臨床診療の変化、人口動態の変化、技術の進歩、患者の期待の進化を反映した、相互に関連するいくつかの要因によって牽引されています。最も顕著な促進要因の一つは、静脈血栓塞栓症の主要な危険因子である座りがちな生活や肥満の世界の増加です。高齢者は運動能力の低下、併存疾患、入院率の高さなどから血栓症を発症しやすいため、高齢化も主要な促進要因の一つです。外科手術、特に整形外科手術の増加に伴い、入院中および回復期に血栓予防薬を必要とする患者が増加しています。医薬品面では、直接経口抗凝固薬（DOAC）の導入と普及により、DVT治療がより身近で安全なものとなり、コンプライアンスが向上し、患者に広く受け入れられるようになりました。さらに、医療用画像や診断の進歩により、より早期かつ正確な発見が可能となり、タイムリーな介入に不可欠となっています。DVTの兆候、リスク、結果に関する医師と一般市民の意識の高まりは、早期の診察と予防行動を促進しています。遠隔モニタリング、モバイルアプリ、電子カルテにより、より一貫したフォローアップとケアコーディネーションが容易になるため、ヘルスケアのデジタル化も一役買っています。DVTの予防と管理に対する政府やヘルスケア支払者からの政策的支援（スクリーニングや薬物治療に対する償還を含む）は、市場の需要を後押ししています。最後に、院内感染や患者の安全性を重視する傾向が強まり、病院は標準化されたDVT予防プログラムを実施するようになっています。これらの促進要因を総合すると、DVT治療と診断の市場が拡大するだけでなく、患者の転帰を改善し、長期的なヘルスケアコストを削減することにもつながります。

セグメント

薬剤クラス別（抗凝固薬、ヘパリン、その他薬剤タイプ）;治療法別（手術、薬剤、その他治療タイプ）;エンドユーザー別（病院エンドユーザー、専門クリニックエンドユーザー、学術・CROエンドユーザー、その他エンドユーザー）

調査対象企業の例

  • 3M Healthcare
  • Arjo
  • Aspen Medical Products
  • Bayer AG
  • Becton, Dickinson and Co.
  • BioCompression Systems Inc.
  • Boston Scientific Corp.
  • Cardinal Health
  • Covidien（Medtronic）
  • Encompass Group, LLC
  • GE HealthCare
  • Huntleigh Healthcare（Arjo）
  • Koninklijke Philips N.V.
  • Medline Industries, LP
  • Medtronic plc
  • Molnlycke Health Care
  • Stryker Corporation
  • ThermoTek, Inc.
  • Tactile Medical
  • Zimmer Biomet Holdings, Inc.

AIインテグレーション

当社は、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界別SLMのクエリに従う代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP38690

Global Deep Vein Thrombosis (DVT) Market to Reach US$1.0 Billion by 2030

The global market for Deep Vein Thrombosis (DVT) estimated at US$681.0 Million in the year 2024, is expected to reach US$1.0 Billion by 2030, growing at a CAGR of 7.3% over the analysis period 2024-2030. Anticoagulants, one of the segments analyzed in the report, is expected to record a 8.4% CAGR and reach US$720.2 Million by the end of the analysis period. Growth in the Heparin segment is estimated at 4.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$185.5 Million While China is Forecast to Grow at 11.6% CAGR

The Deep Vein Thrombosis (DVT) market in the U.S. is estimated at US$185.5 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$220.6 Million by the year 2030 trailing a CAGR of 11.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.5% and 7.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.8% CAGR.

Global Deep Vein Thrombosis (DVT) Market - Key Trends & Drivers Summarized

Why Is Deep Vein Thrombosis Considered a Growing Global Health Concern?

Deep Vein Thrombosis (DVT) has become an increasingly significant health concern across the globe due to its rising prevalence, serious complications, and often silent progression. DVT occurs when a blood clot forms in a deep vein, typically in the legs, and can lead to life-threatening conditions such as pulmonary embolism if the clot dislodges and travels to the lungs. One of the major challenges in managing DVT is that it often develops without noticeable symptoms, making early detection difficult and underscoring the need for awareness and preventative care. The growing incidence of sedentary lifestyles, prolonged immobility, obesity, smoking, and aging populations are all key contributors to the increase in DVT cases worldwide. Long-distance travel, particularly air travel, and extended bed rest after surgeries or during chronic illness are known triggers for clot formation. Additionally, individuals with inherited clotting disorders, cancer patients, and pregnant women face a heightened risk. In hospital settings, DVT is a common postoperative complication, especially following orthopedic procedures like hip and knee replacements. As global populations age and chronic diseases become more prevalent, the burden of DVT on healthcare systems is expected to rise. What makes this condition particularly dangerous is its capacity to recur and the long-term complications it can cause, including post-thrombotic syndrome, which affects mobility and quality of life. Given the potential severity and frequency of DVT, it is increasingly viewed as a public health priority that demands greater screening, awareness campaigns, and preventive strategies.

How Are Technological and Clinical Innovations Improving DVT Diagnosis and Treatment?

Advancements in diagnostic technologies and therapeutic approaches are significantly enhancing the early detection, management, and treatment of Deep Vein Thrombosis. The adoption of duplex ultrasonography as a standard, non-invasive imaging technique has greatly improved the accuracy and accessibility of DVT diagnosis, enabling clinicians to visualize blood flow and detect clots in real time. High-sensitivity D-dimer blood tests have also emerged as essential tools for ruling out DVT in patients with low to moderate risk, reducing unnecessary imaging procedures. On the treatment front, anticoagulants remain the first line of defense, with newer direct oral anticoagulants (DOACs) offering greater convenience and safety profiles compared to traditional therapies like warfarin, which require regular blood monitoring and dietary restrictions. These newer drugs have simplified long-term DVT management and reduced hospital readmissions. Innovations in interventional radiology have introduced catheter-directed thrombolysis and mechanical thrombectomy techniques, which are particularly valuable in cases of large or life-threatening clots. Compression therapy and wearable medical devices are also being used to manage symptoms and reduce the risk of recurrence. Furthermore, digital health platforms and telemedicine are improving patient adherence and follow-up care, especially in remote or underserved regions. Clinical guidelines are evolving to emphasize risk stratification and individualized care plans, encouraging more proactive approaches in high-risk populations. With research continuing into genetic markers and biomarkers for clotting risk, the future of DVT management is likely to become increasingly personalized and precise, reducing both the clinical and economic burden of this condition.

What Market Trends Are Influencing the Growing Demand for DVT Therapies and Monitoring Tools?

Several emerging market trends are contributing to the growing demand for Deep Vein Thrombosis treatments, monitoring technologies, and preventative solutions across healthcare systems globally. One prominent trend is the rising incidence of chronic diseases and conditions that predispose individuals to DVT, such as cardiovascular disease, cancer, and diabetes, especially in aging populations. As healthcare systems adapt to the needs of older adults and those with complex comorbidities, DVT prevention and management are being integrated more widely into routine care. The increased rate of surgeries, particularly orthopedic and cardiovascular procedures, is also influencing market growth, as postoperative patients are at elevated risk for clot formation. In parallel, the expansion of outpatient surgical centers and shorter hospital stays have created a demand for at-home anticoagulation therapies and mobile monitoring devices. Wearable health technologies and digital therapeutics are gaining popularity, offering real-time tracking of circulatory health and medication adherence. There is also a growing emphasis on patient education and self-management, driven by awareness campaigns from public health organizations and patient advocacy groups. In the pharmaceutical space, competition among manufacturers of anticoagulants is intensifying, prompting investment in research to develop safer and more effective formulations with fewer side effects. The increasing use of predictive analytics and AI in healthcare is supporting earlier identification of at-risk individuals, allowing for preemptive intervention. Globally, healthcare policies promoting preventive care and value-based reimbursement models are encouraging providers to adopt comprehensive DVT prevention protocols. These market dynamics are collectively creating an ecosystem where innovation, accessibility, and prevention converge to address a serious and growing health issue.

What Are the Key Drivers Fueling the Expansion of the Global DVT Management Market?

The growth in the Deep Vein Thrombosis market is driven by several interrelated factors that reflect changes in clinical practice, demographic shifts, technological advancements, and evolving patient expectations. One of the most prominent drivers is the global increase in sedentary behavior and obesity, which are major risk factors for venous thromboembolism. The aging population is another major driver, as elderly individuals are more prone to clotting due to reduced mobility, comorbidities, and higher rates of hospitalization. A parallel rise in surgical procedures, particularly orthopedic surgeries, is expanding the pool of individuals requiring thromboprophylaxis both in-hospital and during recovery. On the pharmaceutical front, the introduction and widespread adoption of direct oral anticoagulants (DOACs) are making DVT treatment more accessible and safer, leading to better compliance and broader patient acceptance. Additionally, advances in medical imaging and diagnostics are enabling earlier and more accurate detection, which is critical for timely intervention. Growing awareness among both physicians and the general public about the signs, risks, and consequences of DVT is promoting earlier consultations and preventive behaviors. The digital transformation of healthcare is also playing a role, as remote monitoring, mobile apps, and electronic health records facilitate more consistent follow-up and care coordination. Policy support from governments and healthcare payers for DVT prevention and management, including reimbursement for screenings and medications, is boosting market demand. Finally, an increased focus on hospital-acquired conditions and patient safety metrics is prompting hospitals to implement standardized DVT prevention programs. Collectively, these drivers are not only expanding the market for DVT treatments and diagnostics but also improving patient outcomes and reducing long-term healthcare costs.

SCOPE OF STUDY:

The report analyzes the Deep Vein Thrombosis (DVT) market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Class (Anticoagulants, Heparin, Other Drug Type); Treatment (Surgery, Drugs, Other Treatment Type); End-User (Hospitals End-User, Specialty Clinics End-User, Academic & CROs End-User, Other End-Users)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

  • 3M Healthcare
  • Arjo
  • Aspen Medical Products
  • Bayer AG
  • Becton, Dickinson and Co.
  • BioCompression Systems Inc.
  • Boston Scientific Corp.
  • Cardinal Health
  • Covidien (Medtronic)
  • Encompass Group, LLC
  • GE HealthCare
  • Huntleigh Healthcare (Arjo)
  • Koninklijke Philips N.V.
  • Medline Industries, LP
  • Medtronic plc
  • Molnlycke Health Care
  • Stryker Corporation
  • ThermoTek, Inc.
  • Tactile Medical
  • Zimmer Biomet Holdings, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Deep Vein Thrombosis (DVT) - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Sedentary Lifestyles and Aging Populations Drive the Global Burden of Deep Vein Thrombosis
    • Increased Awareness Campaigns and Early Screening Programs Strengthen the Business Case for DVT Diagnostic Solutions
    • Growing Post-Surgical and Hospital-Associated Risk Factors Expand the Addressable Market for DVT Prevention and Treatment
    • Here's the Story: How Air Travel, Obesity, and Hormonal Therapies Are Contributing to the Rise in DVT Incidence Rates
    • Advancements in Compression Therapy and Wearable VTE Prevention Devices Drive Non-Invasive Treatment Adoption
    • Rising Demand for Anticoagulant Therapies and DOACs Spurs Innovation in Safer and More Convenient DVT Drug Formulations
    • Here's How AI-Enabled Ultrasound and Diagnostic Tools Are Improving Early Detection and Risk Stratification in Clinical Settings
    • Increasing Use of Risk Assessment Models in Hospitals Supports Proactive DVT Management and Prophylaxis Programs
    • Technological Innovation in Interventional Therapies Such as Catheter-Directed Thrombolysis Expands Options for Severe DVT
    • Rising Incidence of DVT in Cancer and Oncology Patients Generates Demand for Specialized Therapeutic Approaches
    • Here's How Telemedicine and Digital Health Platforms Are Supporting DVT Management in Remote and At-Risk Populations
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Deep Vein Thrombosis (DVT) Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Deep Vein Thrombosis (DVT) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Deep Vein Thrombosis (DVT) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Anticoagulants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Anticoagulants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Anticoagulants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Heparin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Heparin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Heparin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Other Drug Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Other End-Users by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Hospitals End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Hospitals End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Hospitals End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Specialty Clinics End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Specialty Clinics End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Specialty Clinics End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Academic & CROs End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Academic & CROs End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Academic & CROs End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Surgery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Surgery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Surgery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: World 16-Year Perspective for Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Other Treatment Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Other Treatment Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: World 16-Year Perspective for Other Treatment Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Deep Vein Thrombosis (DVT) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 35: USA Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by Drug Class - Anticoagulants, Heparin and Other Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Deep Vein Thrombosis (DVT) by Drug Class - Anticoagulants, Heparin and Other Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Deep Vein Thrombosis (DVT) by Drug Class - Percentage Breakdown of Value Sales for Anticoagulants, Heparin and Other Drug Type for the Years 2014, 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by End-user - Other End-Users, Hospitals End-User, Specialty Clinics End-User and Academic & CROs End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Deep Vein Thrombosis (DVT) by End-user - Other End-Users, Hospitals End-User, Specialty Clinics End-User and Academic & CROs End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Deep Vein Thrombosis (DVT) by End-user - Percentage Breakdown of Value Sales for Other End-Users, Hospitals End-User, Specialty Clinics End-User and Academic & CROs End-User for the Years 2014, 2025 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by Treatment - Surgery, Drugs and Other Treatment Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Deep Vein Thrombosis (DVT) by Treatment - Surgery, Drugs and Other Treatment Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: USA 16-Year Perspective for Deep Vein Thrombosis (DVT) by Treatment - Percentage Breakdown of Value Sales for Surgery, Drugs and Other Treatment Type for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by Drug Class - Anticoagulants, Heparin and Other Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Deep Vein Thrombosis (DVT) by Drug Class - Anticoagulants, Heparin and Other Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: Canada 16-Year Perspective for Deep Vein Thrombosis (DVT) by Drug Class - Percentage Breakdown of Value Sales for Anticoagulants, Heparin and Other Drug Type for the Years 2014, 2025 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by End-user - Other End-Users, Hospitals End-User, Specialty Clinics End-User and Academic & CROs End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Deep Vein Thrombosis (DVT) by End-user - Other End-Users, Hospitals End-User, Specialty Clinics End-User and Academic & CROs End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Deep Vein Thrombosis (DVT) by End-user - Percentage Breakdown of Value Sales for Other End-Users, Hospitals End-User, Specialty Clinics End-User and Academic & CROs End-User for the Years 2014, 2025 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by Treatment - Surgery, Drugs and Other Treatment Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Deep Vein Thrombosis (DVT) by Treatment - Surgery, Drugs and Other Treatment Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: Canada 16-Year Perspective for Deep Vein Thrombosis (DVT) by Treatment - Percentage Breakdown of Value Sales for Surgery, Drugs and Other Treatment Type for the Years 2014, 2025 & 2030
  • JAPAN
    • Deep Vein Thrombosis (DVT) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by Drug Class - Anticoagulants, Heparin and Other Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Deep Vein Thrombosis (DVT) by Drug Class - Anticoagulants, Heparin and Other Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: Japan 16-Year Perspective for Deep Vein Thrombosis (DVT) by Drug Class - Percentage Breakdown of Value Sales for Anticoagulants, Heparin and Other Drug Type for the Years 2014, 2025 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by End-user - Other End-Users, Hospitals End-User, Specialty Clinics End-User and Academic & CROs End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Deep Vein Thrombosis (DVT) by End-user - Other End-Users, Hospitals End-User, Specialty Clinics End-User and Academic & CROs End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: Japan 16-Year Perspective for Deep Vein Thrombosis (DVT) by End-user - Percentage Breakdown of Value Sales for Other End-Users, Hospitals End-User, Specialty Clinics End-User and Academic & CROs End-User for the Years 2014, 2025 & 2030
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by Treatment - Surgery, Drugs and Other Treatment Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Deep Vein Thrombosis (DVT) by Treatment - Surgery, Drugs and Other Treatment Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: Japan 16-Year Perspective for Deep Vein Thrombosis (DVT) by Treatment - Percentage Breakdown of Value Sales for Surgery, Drugs and Other Treatment Type for the Years 2014, 2025 & 2030
  • CHINA
    • Deep Vein Thrombosis (DVT) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 62: China Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by Drug Class - Anticoagulants, Heparin and Other Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Deep Vein Thrombosis (DVT) by Drug Class - Anticoagulants, Heparin and Other Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: China 16-Year Perspective for Deep Vein Thrombosis (DVT) by Drug Class - Percentage Breakdown of Value Sales for Anticoagulants, Heparin and Other Drug Type for the Years 2014, 2025 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by End-user - Other End-Users, Hospitals End-User, Specialty Clinics End-User and Academic & CROs End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Deep Vein Thrombosis (DVT) by End-user - Other End-Users, Hospitals End-User, Specialty Clinics End-User and Academic & CROs End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: China 16-Year Perspective for Deep Vein Thrombosis (DVT) by End-user - Percentage Breakdown of Value Sales for Other End-Users, Hospitals End-User, Specialty Clinics End-User and Academic & CROs End-User for the Years 2014, 2025 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by Treatment - Surgery, Drugs and Other Treatment Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Deep Vein Thrombosis (DVT) by Treatment - Surgery, Drugs and Other Treatment Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: China 16-Year Perspective for Deep Vein Thrombosis (DVT) by Treatment - Percentage Breakdown of Value Sales for Surgery, Drugs and Other Treatment Type for the Years 2014, 2025 & 2030
  • EUROPE
    • Deep Vein Thrombosis (DVT) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Deep Vein Thrombosis (DVT) by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: Europe 16-Year Perspective for Deep Vein Thrombosis (DVT) by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by Drug Class - Anticoagulants, Heparin and Other Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Deep Vein Thrombosis (DVT) by Drug Class - Anticoagulants, Heparin and Other Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Deep Vein Thrombosis (DVT) by Drug Class - Percentage Breakdown of Value Sales for Anticoagulants, Heparin and Other Drug Type for the Years 2014, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by End-user - Other End-Users, Hospitals End-User, Specialty Clinics End-User and Academic & CROs End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Deep Vein Thrombosis (DVT) by End-user - Other End-Users, Hospitals End-User, Specialty Clinics End-User and Academic & CROs End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Deep Vein Thrombosis (DVT) by End-user - Percentage Breakdown of Value Sales for Other End-Users, Hospitals End-User, Specialty Clinics End-User and Academic & CROs End-User for the Years 2014, 2025 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by Treatment - Surgery, Drugs and Other Treatment Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Deep Vein Thrombosis (DVT) by Treatment - Surgery, Drugs and Other Treatment Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: Europe 16-Year Perspective for Deep Vein Thrombosis (DVT) by Treatment - Percentage Breakdown of Value Sales for Surgery, Drugs and Other Treatment Type for the Years 2014, 2025 & 2030
  • FRANCE
    • Deep Vein Thrombosis (DVT) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 83: France Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by Drug Class - Anticoagulants, Heparin and Other Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Deep Vein Thrombosis (DVT) by Drug Class - Anticoagulants, Heparin and Other Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: France 16-Year Perspective for Deep Vein Thrombosis (DVT) by Drug Class - Percentage Breakdown of Value Sales for Anticoagulants, Heparin and Other Drug Type for the Years 2014, 2025 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by End-user - Other End-Users, Hospitals End-User, Specialty Clinics End-User and Academic & CROs End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Deep Vein Thrombosis (DVT) by End-user - Other End-Users, Hospitals End-User, Specialty Clinics End-User and Academic & CROs End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: France 16-Year Perspective for Deep Vein Thrombosis (DVT) by End-user - Percentage Breakdown of Value Sales for Other End-Users, Hospitals End-User, Specialty Clinics End-User and Academic & CROs End-User for the Years 2014, 2025 & 2030
    • TABLE 89: France Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by Treatment - Surgery, Drugs and Other Treatment Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Deep Vein Thrombosis (DVT) by Treatment - Surgery, Drugs and Other Treatment Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: France 16-Year Perspective for Deep Vein Thrombosis (DVT) by Treatment - Percentage Breakdown of Value Sales for Surgery, Drugs and Other Treatment Type for the Years 2014, 2025 & 2030
  • GERMANY
    • Deep Vein Thrombosis (DVT) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by Drug Class - Anticoagulants, Heparin and Other Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Deep Vein Thrombosis (DVT) by Drug Class - Anticoagulants, Heparin and Other Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: Germany 16-Year Perspective for Deep Vein Thrombosis (DVT) by Drug Class - Percentage Breakdown of Value Sales for Anticoagulants, Heparin and Other Drug Type for the Years 2014, 2025 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by End-user - Other End-Users, Hospitals End-User, Specialty Clinics End-User and Academic & CROs End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Deep Vein Thrombosis (DVT) by End-user - Other End-Users, Hospitals End-User, Specialty Clinics End-User and Academic & CROs End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: Germany 16-Year Perspective for Deep Vein Thrombosis (DVT) by End-user - Percentage Breakdown of Value Sales for Other End-Users, Hospitals End-User, Specialty Clinics End-User and Academic & CROs End-User for the Years 2014, 2025 & 2030
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by Treatment - Surgery, Drugs and Other Treatment Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Deep Vein Thrombosis (DVT) by Treatment - Surgery, Drugs and Other Treatment Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: Germany 16-Year Perspective for Deep Vein Thrombosis (DVT) by Treatment - Percentage Breakdown of Value Sales for Surgery, Drugs and Other Treatment Type for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by Drug Class - Anticoagulants, Heparin and Other Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Deep Vein Thrombosis (DVT) by Drug Class - Anticoagulants, Heparin and Other Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Italy 16-Year Perspective for Deep Vein Thrombosis (DVT) by Drug Class - Percentage Breakdown of Value Sales for Anticoagulants, Heparin and Other Drug Type for the Years 2014, 2025 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by End-user - Other End-Users, Hospitals End-User, Specialty Clinics End-User and Academic & CROs End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Deep Vein Thrombosis (DVT) by End-user - Other End-Users, Hospitals End-User, Specialty Clinics End-User and Academic & CROs End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: Italy 16-Year Perspective for Deep Vein Thrombosis (DVT) by End-user - Percentage Breakdown of Value Sales for Other End-Users, Hospitals End-User, Specialty Clinics End-User and Academic & CROs End-User for the Years 2014, 2025 & 2030
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by Treatment - Surgery, Drugs and Other Treatment Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Deep Vein Thrombosis (DVT) by Treatment - Surgery, Drugs and Other Treatment Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: Italy 16-Year Perspective for Deep Vein Thrombosis (DVT) by Treatment - Percentage Breakdown of Value Sales for Surgery, Drugs and Other Treatment Type for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Deep Vein Thrombosis (DVT) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 110: UK Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by Drug Class - Anticoagulants, Heparin and Other Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Deep Vein Thrombosis (DVT) by Drug Class - Anticoagulants, Heparin and Other Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: UK 16-Year Perspective for Deep Vein Thrombosis (DVT) by Drug Class - Percentage Breakdown of Value Sales for Anticoagulants, Heparin and Other Drug Type for the Years 2014, 2025 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by End-user - Other End-Users, Hospitals End-User, Specialty Clinics End-User and Academic & CROs End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Deep Vein Thrombosis (DVT) by End-user - Other End-Users, Hospitals End-User, Specialty Clinics End-User and Academic & CROs End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 115: UK 16-Year Perspective for Deep Vein Thrombosis (DVT) by End-user - Percentage Breakdown of Value Sales for Other End-Users, Hospitals End-User, Specialty Clinics End-User and Academic & CROs End-User for the Years 2014, 2025 & 2030
    • TABLE 116: UK Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by Treatment - Surgery, Drugs and Other Treatment Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Deep Vein Thrombosis (DVT) by Treatment - Surgery, Drugs and Other Treatment Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 118: UK 16-Year Perspective for Deep Vein Thrombosis (DVT) by Treatment - Percentage Breakdown of Value Sales for Surgery, Drugs and Other Treatment Type for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by Drug Class - Anticoagulants, Heparin and Other Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Deep Vein Thrombosis (DVT) by Drug Class - Anticoagulants, Heparin and Other Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 121: Spain 16-Year Perspective for Deep Vein Thrombosis (DVT) by Drug Class - Percentage Breakdown of Value Sales for Anticoagulants, Heparin and Other Drug Type for the Years 2014, 2025 & 2030
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by End-user - Other End-Users, Hospitals End-User, Specialty Clinics End-User and Academic & CROs End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Deep Vein Thrombosis (DVT) by End-user - Other End-Users, Hospitals End-User, Specialty Clinics End-User and Academic & CROs End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 124: Spain 16-Year Perspective for Deep Vein Thrombosis (DVT) by End-user - Percentage Breakdown of Value Sales for Other End-Users, Hospitals End-User, Specialty Clinics End-User and Academic & CROs End-User for the Years 2014, 2025 & 2030
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by Treatment - Surgery, Drugs and Other Treatment Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Deep Vein Thrombosis (DVT) by Treatment - Surgery, Drugs and Other Treatment Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 127: Spain 16-Year Perspective for Deep Vein Thrombosis (DVT) by Treatment - Percentage Breakdown of Value Sales for Surgery, Drugs and Other Treatment Type for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by Drug Class - Anticoagulants, Heparin and Other Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Deep Vein Thrombosis (DVT) by Drug Class - Anticoagulants, Heparin and Other Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 130: Russia 16-Year Perspective for Deep Vein Thrombosis (DVT) by Drug Class - Percentage Breakdown of Value Sales for Anticoagulants, Heparin and Other Drug Type for the Years 2014, 2025 & 2030
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by End-user - Other End-Users, Hospitals End-User, Specialty Clinics End-User and Academic & CROs End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Deep Vein Thrombosis (DVT) by End-user - Other End-Users, Hospitals End-User, Specialty Clinics End-User and Academic & CROs End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 133: Russia 16-Year Perspective for Deep Vein Thrombosis (DVT) by End-user - Percentage Breakdown of Value Sales for Other End-Users, Hospitals End-User, Specialty Clinics End-User and Academic & CROs End-User for the Years 2014, 2025 & 2030
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by Treatment - Surgery, Drugs and Other Treatment Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Deep Vein Thrombosis (DVT) by Treatment - Surgery, Drugs and Other Treatment Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 136: Russia 16-Year Perspective for Deep Vein Thrombosis (DVT) by Treatment - Percentage Breakdown of Value Sales for Surgery, Drugs and Other Treatment Type for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by Drug Class - Anticoagulants, Heparin and Other Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Deep Vein Thrombosis (DVT) by Drug Class - Anticoagulants, Heparin and Other Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 139: Rest of Europe 16-Year Perspective for Deep Vein Thrombosis (DVT) by Drug Class - Percentage Breakdown of Value Sales for Anticoagulants, Heparin and Other Drug Type for the Years 2014, 2025 & 2030
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by End-user - Other End-Users, Hospitals End-User, Specialty Clinics End-User and Academic & CROs End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Deep Vein Thrombosis (DVT) by End-user - Other End-Users, Hospitals End-User, Specialty Clinics End-User and Academic & CROs End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 142: Rest of Europe 16-Year Perspective for Deep Vein Thrombosis (DVT) by End-user - Percentage Breakdown of Value Sales for Other End-Users, Hospitals End-User, Specialty Clinics End-User and Academic & CROs End-User for the Years 2014, 2025 & 2030
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by Treatment - Surgery, Drugs and Other Treatment Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Deep Vein Thrombosis (DVT) by Treatment - Surgery, Drugs and Other Treatment Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 145: Rest of Europe 16-Year Perspective for Deep Vein Thrombosis (DVT) by Treatment - Percentage Breakdown of Value Sales for Surgery, Drugs and Other Treatment Type for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Deep Vein Thrombosis (DVT) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Deep Vein Thrombosis (DVT) by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 16-Year Perspective for Deep Vein Thrombosis (DVT) by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by Drug Class - Anticoagulants, Heparin and Other Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Deep Vein Thrombosis (DVT) by Drug Class - Anticoagulants, Heparin and Other Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 16-Year Perspective for Deep Vein Thrombosis (DVT) by Drug Class - Percentage Breakdown of Value Sales for Anticoagulants, Heparin and Other Drug Type for the Years 2014, 2025 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by End-user - Other End-Users, Hospitals End-User, Specialty Clinics End-User and Academic & CROs End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Deep Vein Thrombosis (DVT) by End-user - Other End-Users, Hospitals End-User, Specialty Clinics End-User and Academic & CROs End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 16-Year Perspective for Deep Vein Thrombosis (DVT) by End-user - Percentage Breakdown of Value Sales for Other End-Users, Hospitals End-User, Specialty Clinics End-User and Academic & CROs End-User for the Years 2014, 2025 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by Treatment - Surgery, Drugs and Other Treatment Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Deep Vein Thrombosis (DVT) by Treatment - Surgery, Drugs and Other Treatment Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 157: Asia-Pacific 16-Year Perspective for Deep Vein Thrombosis (DVT) by Treatment - Percentage Breakdown of Value Sales for Surgery, Drugs and Other Treatment Type for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Deep Vein Thrombosis (DVT) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by Drug Class - Anticoagulants, Heparin and Other Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Deep Vein Thrombosis (DVT) by Drug Class - Anticoagulants, Heparin and Other Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 160: Australia 16-Year Perspective for Deep Vein Thrombosis (DVT) by Drug Class - Percentage Breakdown of Value Sales for Anticoagulants, Heparin and Other Drug Type for the Years 2014, 2025 & 2030
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by End-user - Other End-Users, Hospitals End-User, Specialty Clinics End-User and Academic & CROs End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Deep Vein Thrombosis (DVT) by End-user - Other End-Users, Hospitals End-User, Specialty Clinics End-User and Academic & CROs End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 163: Australia 16-Year Perspective for Deep Vein Thrombosis (DVT) by End-user - Percentage Breakdown of Value Sales for Other End-Users, Hospitals End-User, Specialty Clinics End-User and Academic & CROs End-User for the Years 2014, 2025 & 2030
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by Treatment - Surgery, Drugs and Other Treatment Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Deep Vein Thrombosis (DVT) by Treatment - Surgery, Drugs and Other Treatment Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 166: Australia 16-Year Perspective for Deep Vein Thrombosis (DVT) by Treatment - Percentage Breakdown of Value Sales for Surgery, Drugs and Other Treatment Type for the Years 2014, 2025 & 2030
  • INDIA
    • Deep Vein Thrombosis (DVT) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 167: India Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by Drug Class - Anticoagulants, Heparin and Other Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Deep Vein Thrombosis (DVT) by Drug Class - Anticoagulants, Heparin and Other Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 169: India 16-Year Perspective for Deep Vein Thrombosis (DVT) by Drug Class - Percentage Breakdown of Value Sales for Anticoagulants, Heparin and Other Drug Type for the Years 2014, 2025 & 2030
    • TABLE 170: India Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by End-user - Other End-Users, Hospitals End-User, Specialty Clinics End-User and Academic & CROs End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Deep Vein Thrombosis (DVT) by End-user - Other End-Users, Hospitals End-User, Specialty Clinics End-User and Academic & CROs End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 172: India 16-Year Perspective for Deep Vein Thrombosis (DVT) by End-user - Percentage Breakdown of Value Sales for Other End-Users, Hospitals End-User, Specialty Clinics End-User and Academic & CROs End-User for the Years 2014, 2025 & 2030
    • TABLE 173: India Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by Treatment - Surgery, Drugs and Other Treatment Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Deep Vein Thrombosis (DVT) by Treatment - Surgery, Drugs and Other Treatment Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 175: India 16-Year Perspective for Deep Vein Thrombosis (DVT) by Treatment - Percentage Breakdown of Value Sales for Surgery, Drugs and Other Treatment Type for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by Drug Class - Anticoagulants, Heparin and Other Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Deep Vein Thrombosis (DVT) by Drug Class - Anticoagulants, Heparin and Other Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 178: South Korea 16-Year Perspective for Deep Vein Thrombosis (DVT) by Drug Class - Percentage Breakdown of Value Sales for Anticoagulants, Heparin and Other Drug Type for the Years 2014, 2025 & 2030
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by End-user - Other End-Users, Hospitals End-User, Specialty Clinics End-User and Academic & CROs End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Deep Vein Thrombosis (DVT) by End-user - Other End-Users, Hospitals End-User, Specialty Clinics End-User and Academic & CROs End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 181: South Korea 16-Year Perspective for Deep Vein Thrombosis (DVT) by End-user - Percentage Breakdown of Value Sales for Other End-Users, Hospitals End-User, Specialty Clinics End-User and Academic & CROs End-User for the Years 2014, 2025 & 2030
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by Treatment - Surgery, Drugs and Other Treatment Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Deep Vein Thrombosis (DVT) by Treatment - Surgery, Drugs and Other Treatment Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 184: South Korea 16-Year Perspective for Deep Vein Thrombosis (DVT) by Treatment - Percentage Breakdown of Value Sales for Surgery, Drugs and Other Treatment Type for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by Drug Class - Anticoagulants, Heparin and Other Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Deep Vein Thrombosis (DVT) by Drug Class - Anticoagulants, Heparin and Other Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 16-Year Perspective for Deep Vein Thrombosis (DVT) by Drug Class - Percentage Breakdown of Value Sales for Anticoagulants, Heparin and Other Drug Type for the Years 2014, 2025 & 2030
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by End-user - Other End-Users, Hospitals End-User, Specialty Clinics End-User and Academic & CROs End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Deep Vein Thrombosis (DVT) by End-user - Other End-Users, Hospitals End-User, Specialty Clinics End-User and Academic & CROs End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 16-Year Perspective for Deep Vein Thrombosis (DVT) by End-user - Percentage Breakdown of Value Sales for Other End-Users, Hospitals End-User, Specialty Clinics End-User and Academic & CROs End-User for the Years 2014, 2025 & 2030
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by Treatment - Surgery, Drugs and Other Treatment Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Deep Vein Thrombosis (DVT) by Treatment - Surgery, Drugs and Other Treatment Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 16-Year Perspective for Deep Vein Thrombosis (DVT) by Treatment - Percentage Breakdown of Value Sales for Surgery, Drugs and Other Treatment Type for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Deep Vein Thrombosis (DVT) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Deep Vein Thrombosis (DVT) by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 196: Latin America 16-Year Perspective for Deep Vein Thrombosis (DVT) by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by Drug Class - Anticoagulants, Heparin and Other Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Deep Vein Thrombosis (DVT) by Drug Class - Anticoagulants, Heparin and Other Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 199: Latin America 16-Year Perspective for Deep Vein Thrombosis (DVT) by Drug Class - Percentage Breakdown of Value Sales for Anticoagulants, Heparin and Other Drug Type for the Years 2014, 2025 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by End-user - Other End-Users, Hospitals End-User, Specialty Clinics End-User and Academic & CROs End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Deep Vein Thrombosis (DVT) by End-user - Other End-Users, Hospitals End-User, Specialty Clinics End-User and Academic & CROs End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 202: Latin America 16-Year Perspective for Deep Vein Thrombosis (DVT) by End-user - Percentage Breakdown of Value Sales for Other End-Users, Hospitals End-User, Specialty Clinics End-User and Academic & CROs End-User for the Years 2014, 2025 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by Treatment - Surgery, Drugs and Other Treatment Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Deep Vein Thrombosis (DVT) by Treatment - Surgery, Drugs and Other Treatment Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 205: Latin America 16-Year Perspective for Deep Vein Thrombosis (DVT) by Treatment - Percentage Breakdown of Value Sales for Surgery, Drugs and Other Treatment Type for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by Drug Class - Anticoagulants, Heparin and Other Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Deep Vein Thrombosis (DVT) by Drug Class - Anticoagulants, Heparin and Other Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 208: Argentina 16-Year Perspective for Deep Vein Thrombosis (DVT) by Drug Class - Percentage Breakdown of Value Sales for Anticoagulants, Heparin and Other Drug Type for the Years 2014, 2025 & 2030
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by End-user - Other End-Users, Hospitals End-User, Specialty Clinics End-User and Academic & CROs End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Deep Vein Thrombosis (DVT) by End-user - Other End-Users, Hospitals End-User, Specialty Clinics End-User and Academic & CROs End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 211: Argentina 16-Year Perspective for Deep Vein Thrombosis (DVT) by End-user - Percentage Breakdown of Value Sales for Other End-Users, Hospitals End-User, Specialty Clinics End-User and Academic & CROs End-User for the Years 2014, 2025 & 2030
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by Treatment - Surgery, Drugs and Other Treatment Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Deep Vein Thrombosis (DVT) by Treatment - Surgery, Drugs and Other Treatment Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 214: Argentina 16-Year Perspective for Deep Vein Thrombosis (DVT) by Treatment - Percentage Breakdown of Value Sales for Surgery, Drugs and Other Treatment Type for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by Drug Class - Anticoagulants, Heparin and Other Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Deep Vein Thrombosis (DVT) by Drug Class - Anticoagulants, Heparin and Other Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 217: Brazil 16-Year Perspective for Deep Vein Thrombosis (DVT) by Drug Class - Percentage Breakdown of Value Sales for Anticoagulants, Heparin and Other Drug Type for the Years 2014, 2025 & 2030
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by End-user - Other End-Users, Hospitals End-User, Specialty Clinics End-User and Academic & CROs End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Deep Vein Thrombosis (DVT) by End-user - Other End-Users, Hospitals End-User, Specialty Clinics End-User and Academic & CROs End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 220: Brazil 16-Year Perspective for Deep Vein Thrombosis (DVT) by End-user - Percentage Breakdown of Value Sales for Other End-Users, Hospitals End-User, Specialty Clinics End-User and Academic & CROs End-User for the Years 2014, 2025 & 2030
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by Treatment - Surgery, Drugs and Other Treatment Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Deep Vein Thrombosis (DVT) by Treatment - Surgery, Drugs and Other Treatment Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 223: Brazil 16-Year Perspective for Deep Vein Thrombosis (DVT) by Treatment - Percentage Breakdown of Value Sales for Surgery, Drugs and Other Treatment Type for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by Drug Class - Anticoagulants, Heparin and Other Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Deep Vein Thrombosis (DVT) by Drug Class - Anticoagulants, Heparin and Other Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 226: Mexico 16-Year Perspective for Deep Vein Thrombosis (DVT) by Drug Class - Percentage Breakdown of Value Sales for Anticoagulants, Heparin and Other Drug Type for the Years 2014, 2025 & 2030
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by End-user - Other End-Users, Hospitals End-User, Specialty Clinics End-User and Academic & CROs End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Deep Vein Thrombosis (DVT) by End-user - Other End-Users, Hospitals End-User, Specialty Clinics End-User and Academic & CROs End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 229: Mexico 16-Year Perspective for Deep Vein Thrombosis (DVT) by End-user - Percentage Breakdown of Value Sales for Other End-Users, Hospitals End-User, Specialty Clinics End-User and Academic & CROs End-User for the Years 2014, 2025 & 2030
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by Treatment - Surgery, Drugs and Other Treatment Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Deep Vein Thrombosis (DVT) by Treatment - Surgery, Drugs and Other Treatment Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 232: Mexico 16-Year Perspective for Deep Vein Thrombosis (DVT) by Treatment - Percentage Breakdown of Value Sales for Surgery, Drugs and Other Treatment Type for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by Drug Class - Anticoagulants, Heparin and Other Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Deep Vein Thrombosis (DVT) by Drug Class - Anticoagulants, Heparin and Other Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 235: Rest of Latin America 16-Year Perspective for Deep Vein Thrombosis (DVT) by Drug Class - Percentage Breakdown of Value Sales for Anticoagulants, Heparin and Other Drug Type for the Years 2014, 2025 & 2030
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by End-user - Other End-Users, Hospitals End-User, Specialty Clinics End-User and Academic & CROs End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Deep Vein Thrombosis (DVT) by End-user - Other End-Users, Hospitals End-User, Specialty Clinics End-User and Academic & CROs End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 238: Rest of Latin America 16-Year Perspective for Deep Vein Thrombosis (DVT) by End-user - Percentage Breakdown of Value Sales for Other End-Users, Hospitals End-User, Specialty Clinics End-User and Academic & CROs End-User for the Years 2014, 2025 & 2030
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by Treatment - Surgery, Drugs and Other Treatment Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Deep Vein Thrombosis (DVT) by Treatment - Surgery, Drugs and Other Treatment Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 241: Rest of Latin America 16-Year Perspective for Deep Vein Thrombosis (DVT) by Treatment - Percentage Breakdown of Value Sales for Surgery, Drugs and Other Treatment Type for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Deep Vein Thrombosis (DVT) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Deep Vein Thrombosis (DVT) by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 244: Middle East 16-Year Perspective for Deep Vein Thrombosis (DVT) by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by Drug Class - Anticoagulants, Heparin and Other Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Deep Vein Thrombosis (DVT) by Drug Class - Anticoagulants, Heparin and Other Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 247: Middle East 16-Year Perspective for Deep Vein Thrombosis (DVT) by Drug Class - Percentage Breakdown of Value Sales for Anticoagulants, Heparin and Other Drug Type for the Years 2014, 2025 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by End-user - Other End-Users, Hospitals End-User, Specialty Clinics End-User and Academic & CROs End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Deep Vein Thrombosis (DVT) by End-user - Other End-Users, Hospitals End-User, Specialty Clinics End-User and Academic & CROs End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 250: Middle East 16-Year Perspective for Deep Vein Thrombosis (DVT) by End-user - Percentage Breakdown of Value Sales for Other End-Users, Hospitals End-User, Specialty Clinics End-User and Academic & CROs End-User for the Years 2014, 2025 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by Treatment - Surgery, Drugs and Other Treatment Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Deep Vein Thrombosis (DVT) by Treatment - Surgery, Drugs and Other Treatment Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 253: Middle East 16-Year Perspective for Deep Vein Thrombosis (DVT) by Treatment - Percentage Breakdown of Value Sales for Surgery, Drugs and Other Treatment Type for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by Drug Class - Anticoagulants, Heparin and Other Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Deep Vein Thrombosis (DVT) by Drug Class - Anticoagulants, Heparin and Other Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 256: Iran 16-Year Perspective for Deep Vein Thrombosis (DVT) by Drug Class - Percentage Breakdown of Value Sales for Anticoagulants, Heparin and Other Drug Type for the Years 2014, 2025 & 2030
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by End-user - Other End-Users, Hospitals End-User, Specialty Clinics End-User and Academic & CROs End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Deep Vein Thrombosis (DVT) by End-user - Other End-Users, Hospitals End-User, Specialty Clinics End-User and Academic & CROs End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 259: Iran 16-Year Perspective for Deep Vein Thrombosis (DVT) by End-user - Percentage Breakdown of Value Sales for Other End-Users, Hospitals End-User, Specialty Clinics End-User and Academic & CROs End-User for the Years 2014, 2025 & 2030
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by Treatment - Surgery, Drugs and Other Treatment Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Deep Vein Thrombosis (DVT) by Treatment - Surgery, Drugs and Other Treatment Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 262: Iran 16-Year Perspective for Deep Vein Thrombosis (DVT) by Treatment - Percentage Breakdown of Value Sales for Surgery, Drugs and Other Treatment Type for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by Drug Class - Anticoagulants, Heparin and Other Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Deep Vein Thrombosis (DVT) by Drug Class - Anticoagulants, Heparin and Other Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 265: Israel 16-Year Perspective for Deep Vein Thrombosis (DVT) by Drug Class - Percentage Breakdown of Value Sales for Anticoagulants, Heparin and Other Drug Type for the Years 2014, 2025 & 2030
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by End-user - Other End-Users, Hospitals End-User, Specialty Clinics End-User and Academic & CROs End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Deep Vein Thrombosis (DVT) by End-user - Other End-Users, Hospitals End-User, Specialty Clinics End-User and Academic & CROs End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 268: Israel 16-Year Perspective for Deep Vein Thrombosis (DVT) by End-user - Percentage Breakdown of Value Sales for Other End-Users, Hospitals End-User, Specialty Clinics End-User and Academic & CROs End-User for the Years 2014, 2025 & 2030
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by Treatment - Surgery, Drugs and Other Treatment Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Deep Vein Thrombosis (DVT) by Treatment - Surgery, Drugs and Other Treatment Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 271: Israel 16-Year Perspective for Deep Vein Thrombosis (DVT) by Treatment - Percentage Breakdown of Value Sales for Surgery, Drugs and Other Treatment Type for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by Drug Class - Anticoagulants, Heparin and Other Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Deep Vein Thrombosis (DVT) by Drug Class - Anticoagulants, Heparin and Other Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 274: Saudi Arabia 16-Year Perspective for Deep Vein Thrombosis (DVT) by Drug Class - Percentage Breakdown of Value Sales for Anticoagulants, Heparin and Other Drug Type for the Years 2014, 2025 & 2030
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by End-user - Other End-Users, Hospitals End-User, Specialty Clinics End-User and Academic & CROs End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Deep Vein Thrombosis (DVT) by End-user - Other End-Users, Hospitals End-User, Specialty Clinics End-User and Academic & CROs End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 277: Saudi Arabia 16-Year Perspective for Deep Vein Thrombosis (DVT) by End-user - Percentage Breakdown of Value Sales for Other End-Users, Hospitals End-User, Specialty Clinics End-User and Academic & CROs End-User for the Years 2014, 2025 & 2030
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by Treatment - Surgery, Drugs and Other Treatment Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Deep Vein Thrombosis (DVT) by Treatment - Surgery, Drugs and Other Treatment Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 280: Saudi Arabia 16-Year Perspective for Deep Vein Thrombosis (DVT) by Treatment - Percentage Breakdown of Value Sales for Surgery, Drugs and Other Treatment Type for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by Drug Class - Anticoagulants, Heparin and Other Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Deep Vein Thrombosis (DVT) by Drug Class - Anticoagulants, Heparin and Other Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 283: UAE 16-Year Perspective for Deep Vein Thrombosis (DVT) by Drug Class - Percentage Breakdown of Value Sales for Anticoagulants, Heparin and Other Drug Type for the Years 2014, 2025 & 2030
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by End-user - Other End-Users, Hospitals End-User, Specialty Clinics End-User and Academic & CROs End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Deep Vein Thrombosis (DVT) by End-user - Other End-Users, Hospitals End-User, Specialty Clinics End-User and Academic & CROs End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 286: UAE 16-Year Perspective for Deep Vein Thrombosis (DVT) by End-user - Percentage Breakdown of Value Sales for Other End-Users, Hospitals End-User, Specialty Clinics End-User and Academic & CROs End-User for the Years 2014, 2025 & 2030
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by Treatment - Surgery, Drugs and Other Treatment Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Deep Vein Thrombosis (DVT) by Treatment - Surgery, Drugs and Other Treatment Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 289: UAE 16-Year Perspective for Deep Vein Thrombosis (DVT) by Treatment - Percentage Breakdown of Value Sales for Surgery, Drugs and Other Treatment Type for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by Drug Class - Anticoagulants, Heparin and Other Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Deep Vein Thrombosis (DVT) by Drug Class - Anticoagulants, Heparin and Other Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 292: Rest of Middle East 16-Year Perspective for Deep Vein Thrombosis (DVT) by Drug Class - Percentage Breakdown of Value Sales for Anticoagulants, Heparin and Other Drug Type for the Years 2014, 2025 & 2030
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by End-user - Other End-Users, Hospitals End-User, Specialty Clinics End-User and Academic & CROs End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Deep Vein Thrombosis (DVT) by End-user - Other End-Users, Hospitals End-User, Specialty Clinics End-User and Academic & CROs End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 295: Rest of Middle East 16-Year Perspective for Deep Vein Thrombosis (DVT) by End-user - Percentage Breakdown of Value Sales for Other End-Users, Hospitals End-User, Specialty Clinics End-User and Academic & CROs End-User for the Years 2014, 2025 & 2030
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by Treatment - Surgery, Drugs and Other Treatment Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Deep Vein Thrombosis (DVT) by Treatment - Surgery, Drugs and Other Treatment Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 298: Rest of Middle East 16-Year Perspective for Deep Vein Thrombosis (DVT) by Treatment - Percentage Breakdown of Value Sales for Surgery, Drugs and Other Treatment Type for the Years 2014, 2025 & 2030
  • AFRICA
    • Deep Vein Thrombosis (DVT) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by Drug Class - Anticoagulants, Heparin and Other Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Deep Vein Thrombosis (DVT) by Drug Class - Anticoagulants, Heparin and Other Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 301: Africa 16-Year Perspective for Deep Vein Thrombosis (DVT) by Drug Class - Percentage Breakdown of Value Sales for Anticoagulants, Heparin and Other Drug Type for the Years 2014, 2025 & 2030
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by End-user - Other End-Users, Hospitals End-User, Specialty Clinics End-User and Academic & CROs End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Deep Vein Thrombosis (DVT) by End-user - Other End-Users, Hospitals End-User, Specialty Clinics End-User and Academic & CROs End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 304: Africa 16-Year Perspective for Deep Vein Thrombosis (DVT) by End-user - Percentage Breakdown of Value Sales for Other End-Users, Hospitals End-User, Specialty Clinics End-User and Academic & CROs End-User for the Years 2014, 2025 & 2030
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by Treatment - Surgery, Drugs and Other Treatment Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Deep Vein Thrombosis (DVT) by Treatment - Surgery, Drugs and Other Treatment Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 307: Africa 16-Year Perspective for Deep Vein Thrombosis (DVT) by Treatment - Percentage Breakdown of Value Sales for Surgery, Drugs and Other Treatment Type for the Years 2014, 2025 & 2030

IV. COMPETITION